Acknowledgement of Reviewers 2018.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 199, doi. 10.1007/s10637-019-00729-z
- Publication type:
- Article
Works matching IS 01676997 AND DT 2019 AND VI 37 AND IP 1
Results: 22
1
2
Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 175, doi. 10.1007/s10637-018-0684-8
- By:
- Publication type:
- Article
3
Antitumor evaluation of novel phenothiazine derivatives that inhibit migration and tubulin polymerization against gastric cancer MGC-803 cells.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 188, doi. 10.1007/s10637-018-0682-x
- By:
- Publication type:
- Article
4
Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 166, doi. 10.1007/s10637-018-0654-1
- By:
- Publication type:
- Article
5
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 159, doi. 10.1007/s10637-018-0650-5
- By:
- Publication type:
- Article
6
First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 147, doi. 10.1007/s10637-018-0646-1
- By:
- Publication type:
- Article
7
Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR<sub>1</sub>-antibody) against human breast cancer cells.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 57, doi. 10.1007/s10637-018-0618-5
- By:
- Publication type:
- Article
8
Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 139, doi. 10.1007/s10637-018-0638-1
- By:
- Publication type:
- Article
9
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 118, doi. 10.1007/s10637-018-0636-3
- By:
- Publication type:
- Article
10
Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 109, doi. 10.1007/s10637-018-0634-5
- By:
- Publication type:
- Article
11
Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 184, doi. 10.1007/s10637-018-0633-6
- By:
- Publication type:
- Article
12
Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 127, doi. 10.1007/s10637-018-0639-0
- By:
- Publication type:
- Article
13
The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancer.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 65, doi. 10.1007/s10637-018-0616-7
- By:
- Publication type:
- Article
14
Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 9, doi. 10.1007/s10637-018-0606-9
- By:
- Publication type:
- Article
15
Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology - phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 35, doi. 10.1007/s10637-018-0611-z
- By:
- Publication type:
- Article
16
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 87, doi. 10.1007/s10637-018-0610-0
- By:
- Publication type:
- Article
17
Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 47, doi. 10.1007/s10637-018-0609-6
- By:
- Publication type:
- Article
18
Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 17, doi. 10.1007/s10637-018-0607-8
- By:
- Publication type:
- Article
19
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 98, doi. 10.1007/s10637-018-0614-9
- By:
- Publication type:
- Article
20
Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 1, doi. 10.1007/s10637-018-0604-y
- By:
- Publication type:
- Article
21
Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 76, doi. 10.1007/s10637-018-0602-0
- By:
- Publication type:
- Article
22
Copper-tolfenamic acid: evaluation of stability and anti-cancer activity.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 1, p. 27, doi. 10.1007/s10637-018-0594-9
- By:
- Publication type:
- Article